Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3354

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3354
---
 and warrants may be volatile, and you could lose all or part of your investment.

    ●
    We
    are a “controlled company” within the meaning of Nasdaq rules and the rules of the SEC. As a result, we qualify for
    exemptions from certain corporate governance requirements that provide protection to shareholders of other companies.

    ●
    Our
    principal stockholders and management own a significant percentage of our common stock and are able to exert significant control
    over matters subject to stockholder approval.

    ●
    Our
    issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans, employee
    stock purchase plan or otherwise will dilute all other stockholders.

    ●
    We
    will incur increased costs as a result of operating as a public company, and our management will devote substantial time to compliance
    with its public company responsibilities and corporate governance practices.

    ●
    Our
    management team has limited experience managing a public company.

    ●
    There
    can be no assurance that we will be able to comply with the continued listing standards of Nasdaq. Our failure to meet the continued
    listing requirements of Nasdaq could result in a delisting of our common stock and warrants.

    ●
    We
    qualify as an “emerging growth company” as well as a “smaller reporting company” within the meaning of the
    Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies,
    this could make our securities less attractive to investors and may make it more difficult to compare our performance with other
    public companies.

8

PART
I

ITEM
1. BUSINESS.

Unless
otherwise noted or the context otherwise requires, the disclosures in this Item 1 refer to Ocean Biomedical, Inc. and its subsidiaries
following the consummation of the Business Combination and all references to “we,” “us,” “our,” “Ocean
Biomedical,” or the “Company,” are to Ocean Biomedical, Inc.

Introduction

We
were originally incorporated in June 2021 as a Delaware corporation under the name “Aesther Healthcare Acquisition Corp.”
We were a special purpose acquisition company, formed for the purpose of effecting an initial business combination with one or more target
companies. On September 17, 2021 (the “IPO Closing Date”), we consummated our initial public offering (the “IPO”
or the “Public Offering”).